Introduction
The benefits of inhaled therapy for the treatment of lung diseases have been recognised for many years. In comparison with oral or parenteral formulations, minute but therapeutic doses of drug are delivered topically into the airways causing local effects within the lung. Unwanted systemic effects are minimised as the medication acts with maximum pulmonary specificity together with a rapid onset and duration of action. Consequently, aerosol formulations of bronchodilators and corticosteroids are the mainstay of modern treatment for asthma and chronic obstructive pulmonary disease (COPD). Central to the success of inhaled treatment has been the availability of efficient aerosol delivery systems or 'inhalers'. To provide consistent clinical control, an appropriate inhaler should satisfy the criteria that are described in Figure 1 .
The pressurised metered dose inhaler (pMDI) was first introduced 50 years ago for the delivery of bronchodilators (1) . It was readily accepted by patients and soon formulated to contain other classes of asthma medications. It was particularly useful for the administration of corticosteroids which hitherto had been administered orally. Because of the large doses needed for oral administration, corticosteroid treatment for asthma was associated with an unacceptably
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Review Criteria
The information presented in this review has been sourced from published literature. In particular, the review has focussed on comparative studies that have measured in vitro aerosol output characteristics of different types of dry powder inhaler, and also clinical studies that have assessed ease of handling and patient preferences for different dry powder inhalers.
high adverse event profile (2) . As a result of the availability of inhaled formulations, with the introduction of beclometasone dipropionate in 1972, inhaled corticosteroids are now part of the cornerstone of asthma treatment. Virtually every class of inhaled drug is now formulated as a pMDI. This small and unobtrusive device remains the most commonly used inhalation device worldwide (3) , with estimates of annual production in excess of 800 million units (4) . A significant factor in its enduring popularity is its advantage of being cheap and relatively simple to manufacture on a large commercial scale and also the availability of a range of drugs that can be formulated for pMDIs.
In addition to pMDIs, dry powder inhalers (DPIs) have been available since 1967. The Spinhaler TM (Aventis) was first introduced for the delivery of sodium cromoglycate (5) . It was developed because it was not possible for a pMDI to accommodate the large (20 mg) required dose of sodium cromoglycate for each administration. To deliver a dose of such magnitude, this aerosol delivery system comprised an inhaler which was supplied with separate capsules. Each gelatin capsule contained a single dose of drug, which was placed inside the inhaler before each use and the empty capsule was discarded. Presentation of the formulation in a capsule also provided protection from moisture ingress. This is essential to maintain good powder flow and ensure that the drug particles have the potential to be deposited in the lungs during normal patient use. The Spinhaler TM was regarded as inconvenient to use because of the number of steps required to administer each dose. Nevertheless, this type of system is still widely used especially when protection of the drug formulation from moisture is important, for example the recent introduction of tiotropium in the Handihaler TM (Boehringer-Ingelheim) device. A DPI has some distinct advantages over pMDIs for the delivery of inhaled drugs to two particular groups of patients. Many children and elderly patients have difficulty using a pMDI correctly, because of the high velocity at which each dose is released and, therefore have problems following the inhalation technique recommended in the Patient Information Leaflet. Extensive training is required to achieve correct use of a pMDI. To deliver the drug effectively into the lung, the patient must actuate the pMDI as they start to inhale. This requires a high degree of 'hand/lung' co-ordination and failure to achieve this often results in reduced effectiveness of treatment and poor disease control (6, 7) . Because the Spinhaler TM required inspiratory effort to draw the medication from the device, drug was only released while the patient inhaled. Therefore, the issue of 'hand-lung' co-ordination was resolved. However, this problem has been substituted by another problem that affects all DPIs. To ensure that the dose emitted from a DPI contains drug particles that have the greatest potential to be delivered to the conducting airways, it is necessary for the patient to generate adequate inspiratory effort. The faster the inspiration rate through the DPI (and hence acceleration), the better is the quality of the emitted dose for lung deposition. This applies to all DPIs, but for some the effect is minimal, whereas other DPIs show significant flow-dependent dose emission, which may result in erratic dose emission and in turn compromise consistent disease control. The latter problem could be overcome by recommending adjustable maintenance dosing regimens to a patient's management plan. Concurrent with the introduction of DPIs was a growing environmental concern that the chlorofluorocarbon propellants used in pMDIs were causing irreparable damage to the ozone layer in the atmosphere (8) . The pharmaceutical industry was therefore committed to the development of nonchlorofluorocarbons (CFC) propellants for use in pMDIs and also DPIs that required no propellant at all. The reformulation to change the propellant used in pMDIs to those based on hydrofluoroalkanes, in place of CFC was not easy and some difficulties still remain. Consequently, other DPIs began to appear on the market. The first such DPIs were similar to the Spinhaler TM , for example salbutamol (9) and beclometasone dipropionate (10) (12) . As the number of different types of DPIs on the market continues to increase, particularly with the advent of generic DPIs, the prescriber may experience some uncertainty in the selection of the optimal inhalation device for any given patient. This may be compounded by recent suggestions that because pMDIs are, in general, cheaper than DPIs, they should be prescribed as first-line treatments for all patients (13, 14) . Furthermore, it has been proposed that it is acceptable to switch patients from more expensive DPIs to pMDIs or generic DPIs without compromising treatment efficacy in asthmatic patients (14) . However, the interchangeability of DPIs has been doubted (15) .
Characteristics and performance of dry powder inhalers
The range of DPIs that are currently available falls into three device categories: single-unit dose inhalers in which each dose is loaded into the device before use; multi-dose reservoir inhalers in which a bulk supply of drug is preloaded into the device and multi-unit dose inhalers in which several single doses are individually sealed and discharged each time the device is actuated. Table 1 summarises the more common DPIs that fall into the three categories. In recent years, there has been a dramatic increase in the number of patent applications for new DPIs and it is anticipated that many more will be introduced in the future. Furthermore, attention has recently focussed on using the pulmonary route to deliver active compounds into the systemic circulation. For example, a DPI formulation of insulin (Exubera, Pfizer in collaboration with Nektar Therapeutics) will soon be available. , may well be beneficial in this population, (21, 22) as well as those with asthma.
Single-unit dose devices

Multi-dose reservoir devices
Multi-dose DPIs, by definition, contain more than one dose of drug. There are two types of multi-dose DPI, reservoir and multi-unit dose devices. Multidose reservoir devices contain a bulk supply of drug from which individual doses are released with each actuation. The first such inhaler to be developed was the Turbuhaler TM (23) which is used to deliver b 2 -agonists and corticosteroids separately and in combination. The drug located within this inhaler is formulated as a pellet of a soft aggregate of micronised drug which may be formulated with or without any additional lactose excipient. To release a dose of drug, the patient twists the base of the device resulting in a dose of drug being shaved off the pellet while holding the inhaler in a vertical position. It is essential that this orientation is used when dose metering all reservoir DPIs, because they rely on gravity to fill the dose metering cup. The dose is then dispersed by turbulent airflow as the patient inhales through the device. This turbulent airflow creates the energy to disperse particles in the emitted dose that are small enough to have a high possibility of depositing in the conducting airways.
Other multi-dose reservoir devices have become available in recent years including the Easyhaler TM (24) , Clickhaler TM (25) and Twisthaler TM (ScheringPlough) (26) . The design of new multi-dose reservoir DPIs has focussed on minimising the flow-dependent dose emission that occurs with the Turbuhaler TM .
Also, attention has been directed to the protection of the formulation from moisture ingress during routine storage and patient use. For example, the Easyhaler TM has a protective case and the hopper is designed, so that it is impossible for the patient to blow into it. Furthermore, all multi-dose reservoir DPIs are packaged with a protective wrapper to prevent moisture ingress prior to dispensing and patient use. The majority of this type of DPIs are disposable and cannot be refilled with additional drug. However, the Novolizer TM (ASTA Medica) is rechargeable and designed to be used with cartridges that contain 200 doses of drug (27) .
Multi-unit dose devices
Multi-unit dose DPIs utilise individually prepared and sealed doses of drug. The first such DPI was the Aerohaler TM which contained six unit dose capsules as a magazine, each delivering one dose of drug. The device was used to deliver fenoterol and ipratropium bromide and was very similar in design to single-unit dose inhalers. The Diskhaler TM is used in conjunction with refill Rotadisks TM which house four or eight sealed blisters containing drug and lactose excipient (28) . Excipients such as lactose improve dose uniformity by increasing the mass of powder for each dose thereby improving the accuracy of dose metering and minimising the effect of inhalation flow-dependent dose emission. The sealed blisters offer a high degree of protection against environmental factors such as humidity and because the premetered doses of drug are factory prepared and separately packaged, dose uniformity is assured. The houses a coiled strip of 60 double foil-wrapped individual doses. The patient operates the inhaler by sliding a lever which moves the next dose-containing blister into place. A ratchet within the inhaler causes the device to click when the next dose is properly positioned. Priming the device in this way simultaneously peels the two layers of foil apart exposing the dose ready for inhalation. The Diskus TM also incorporates a dose counter, which enables the patient to monitor the number of doses remaining in the device, and also has an integral outer case which serves to keep the device dust free and also resets the lever ready for the next dose.
Performance of DPIs
As a result of the wide variation in design characteristics of the many DPIs available, their performance characteristics vary considerably and this may impact their suitability for use in different patient populations. Therefore, it is imperative that before prescribing a DPI for an individual patient, the characteristics of that DPI are known so that its suitability can be assessed. The main factors described in Figure 1 that must be taken into account are summarised in Table 2 .
Drug delivery
It is easy to assume that when an inhaler is actuated, the dose of drug delivered to the patient is the same as that cited on the package (label claim). However, this is not always the case. There are considerable differences in the proportions of the nominal dose (label claim) released from different DPIs which is defined as the total emitted dose (TED). European and American regulatory agencies have now put into place standards that specify output requirements in terms of the quantity and variability in the emitted doses from DPIs (29, 30) . These standards are designed to ensure consistent dosing from DPIs, both throughout the life of an individual DPI and also between inhalers of the same DPI make. The TED is the term used to describe the quantity of drug that is released from an inhaler during a single actuation. Within the TED, therapeutic benefit is derived from the mass of drug particles that are small enough to reach the airways during inhalation. This parameter is described as the fine particle fraction (FPF) or fine particle mass (FPM) and refers to mass of particles released in an actuation that have an aerodynamic diameter of < 5 lm (31). These particles have the greatest potential to be deposited on to the airways during an inhalation. Larger aerosol particles tend to deposit in the oropharynx and are swallowed.
Both the TED and FPF are measured in the laboratory using in vitro pharmacopoeial methods. Using The Diskus inhaler these methods, it has been demonstrated that there is a wide variation in performance, in terms of TED and FPF, from the range of DPIs available as a result of intrinsic design differences. These design differences affect parameters such as the internal resistance of a device which in turn affects the flow rate achieved through the DPI. Figure 3 . Increases in FPM were also observed in parallel with flow rate. Similarly, the FPM of both drugs more than doubled when the flow rate was increased from 30 to 60 l/ min. Figure 3 also highlights that intra-inhaler dose emission can also be erratic. However, this phenomenon was not found for the Easyhaler TM or the Diskus TM when studied at different flow rates (35) as shown in Figure 4 . Large intra-and interinhaler dose emission differences could have clinical consequences in the bronchodilator treatment of asthma exacerbations. Also, because of the absence of immediate therapeutic feedback when inhaling corticosteroids, these differences may also cause problems in achieving adequate asthma or COPD control. Therefore, it is important that a DPI should deliver a consistent dose irrespective of a patient's inspiratory flow rate. The rationale for the presentation of drug as individually, factory-measured unit doses as supplied in Figure 3 The amounts of budesonide and formoterol (expressed as a percentage of the labelled emitted dose) emitted from each dose of the six inhalers tested using in vitro inhalation flow rates of 30, 60 and 90 l/min (reproduced with permission)
the Diskus TM was to ensure a higher degree of dose consistency throughout the life of the device than that achieved in multi-dose reservoir devices (36) . Consistent dosing from the Diskus TM has been found with salmeterol (37), fluticasone propionate (38) and the combination of both salmeterol and fluticasone propionate (39) and is therefore independent of the drug delivered. Figure 4 illustrates the minimal effect of inhalation flow rate on the dose emitted from the Diskus TM . Furthermore, multi-unit dose inhalers, such as Diskus TM have been shown to deliver more consistent doses across a wide range of sampling flow rates than the Turbuhaler TM reservoir multi-dose device (40, 41, 32) .
In vitro techniques such as those described above provide valuable data that gives an indication of where an aerosol may deposit in the airways (42) . However, FPF measured under laboratory conditions cannot be extrapolated into a direct measure of drug deposition (43) . For example, most inertial impaction devices, such as cascade impactors described in the pharmacopoeial methods, sample aerosol from an inhaler by drawing air through the device at a constant sampling flow rate (usually 60 l/min, or the flow rate achieved at a pressure drop of 4 KPa). This is not representative of in vivo use. In practice, the magnitude of airflow passing through the DPI during use is variable and controlled by the patient's ability to inhale. An individual patient's inspiratory capacity is affected by several parameters including lung size, degree of airway obstruction that is present and their inspiratory musculature. In addition to these patient factors, the resistance of the inhaler itself affects the flow rate a patient can achieve when inhaling through the device. Each type of DPI has its own resistance characteristics which are caused by the internal structure of the device and there is considerable variation in this parameter between available DPIs (44) . The higher the internal resistance of a DPI, the lower the flow rate a patient can generate during inhalation at a given inspiratory pressure.
A modification of the aerosol sampling methodology used to obtain the TED and FPF measurements at variable flow rates has been developed. This technique, using the Electronic Lung, employs a variable sampling flow rate which is derived from in vivo recordings of patient breathing patterns. This ex vivo technique enables inhalation profiles from different patient groups to be recorded using a pressure-sensitive device. The recorded profiles are replayed via an electronic synthesiser which exactly copies the patient's inspiration through a sampling device while the aerosol is released from the DPI. Using this technique to simulate the breathing pattern of asthmatic children aged 4-8 years, the TED of fluticasone propionate via the Diskus TM was compared with that of budesonide delivered via the Turbuhaler TM (45 Recently, this technique has been used to estimate the dose that severe asthmatics would receive when inhaling from a Diskus TM (containing 500 mcg fluticasone propionate with 50 mcg salmeterol) and a Turbuhaler TM (containing 200 mcg budesonide and 6 mcg formoterol) (46) . Figure 5 illustrates the range of inspiratory flow rates generated by the patients through the two devices and shows that while that the effect of inhalation flow rate on the dose emitted from the Diskus was minimal, it had a significant effect on that released from the Turbuhaler TM . Figure 6 illustrates that there was an inverse relationship between inspiratory flow rate and mass median aerodynamic diameter (MMAD) of aerosol released from both DPIs. The change in the MMAD with inhalation flow rate was similar for both devices (46) . This decrease in MMAD would counteract the greater potential for more central deposition of particles when using a faster inhalation flow rate. Most DPIs are designed to be used by a spectrum of patients from children to the elderly people with a wide range of severities of asthma symptoms. This variety of patients inherently has different inhalation capacities and therefore generates varying inspiratory flow rates. As small children have smaller inspiratory capacities than adults in terms of both flow rate and volume, DPIs are generally not advocated for children under the age of 6 years. However, Diskus TM operates at low flow rates and has been shown to be effective for use in children aged as young as 4 years (47) . The TED and FPF released by some DPIs have been shown to vary considerably and be affected by differences in inspiratory flow rate (48, 33, 44 (50) . A further study in children highlighted the problems that some may have to generate sufficient inspiratory effort to receive the required dose from a Turbuhaler TM and recommended that this device should not be prescribed to preschool age children (51) . The use of radio-labelled medications allows the in vivo deposition of the aerosol to be observed and , each dose of drug is protected from the environment by moisture proof, sealed aluminium foil units, which are peeled back to expose each dose just as it is used. This has been shown to provide a high level of dose protection (37). In addition to the foil strip, the Diskus TM is also supplied with an outer foil wrapper which provides extra protection from the environment during storage prior to use. A recent study showed that the FPF (but not TED) from the Diskus TM was shown to be reduced by 50% after 3 months of storage at high temperature and humidity (40°C/75% RH), while that from the Turbuhaler TM was not affected to the same extent (56) . However, in this study Diskus TM inhalers were used that had limited unexpired shelf life and no assurance was given regarding the storage conditions of these inhalers prior to their use in this study. Furthermore, the conditions of temperature and humidity under which the aerosol was sampled from the inhalers differed considerably from the conditions under which the inhalers had been stored. It is, therefore, difficult to assess whether the observed changes in FPM were due to the experimental conditions, ambient conditions during sampling or previous storage conditions of the inhalers.
Ease of use
Arguably, the most important criterion in the selection of a DPI is its ease of use. Even if a DPI is shown to have an excellent pharmaceutical performance in terms of drug output, if it is not used correctly then it can be rendered ineffective. The results of a recent survey conducted in 169 patients with asthma or COPD showed that patients rated 'ease of use during an attack' as the most important feature of an ideal inhaler (57) . If patients cannot use an inhaler correctly, their treatment is compromised which may have extremely serious consequences. Dry powder inhaler devices have an inherent advantage over pMDIs, because the dose of drug is only released from the inhaler as the patient inhales. Therefore, it is not necessary for the patient to coordinate inspiration with actuation of the device. However, it is still necessary for the patient to provide a sustained inspiration of adequate flow rate through the inhaler in order for the complete dose to be released. The inspiratory flow rate required for optimum delivery depends on the individual DPI and the ease with which a patient can generate this flow rate depends on the resistance of the individual DPI.
The diverse characteristics of patients who require inhaled medications are such that simplicity of operation is of paramount importance. One study assessed patients' use of their own DPI or pMDI and found that nearly 90% made at least one mistake in their inhalation technique (58) . It is therefore imperative to provide training to patients so that they learn to use their DPIs correctly. It has been shown that effective training increases patients' ability to use a DPI correctly (57, 59) . Table 3 summarises the instructions for use of some popular DPIs (60 (76, 77) .
Patient preference
Patient preference has been identified as the second most important consideration for device selection after ease of use (78). The recognition that patients have distinct personal preferences regarding the inhaler that they use and are able to make informed choices is particularly important in establishing an effective disease management partnership between the healthcare professional and the patient.
Compliance with the treatment is improved when patient and physician work together to achieve effective disease control (79) . Many studies have been conducted to establish patient preference for one device over others. The results show that there is enormous variation in preferred devices. Table 4 summarises the findings of some of the studies in which patient preference for one DPI over another was compared. Although comparative studies are generally designed to show overall preference for one device over another, in reality patients may prefer certain features of one inhaler over those of another inhaler, but not necessarily other features. Therefore, studies have been conducted to identify the most important characteristics or features of an 'ideal' DPI for different groups of patient (80) (81) (82) (83) . The findings of these studies show that different groups of patients or parents have different priorities. For example, parents of children who administer the dose of medication to their child rated that it was more important to them to feel that the child had received the dose than it was for children or adults who self-administer the medication (83) . Similarly, children stated that they preferred a small device that was easy to carry around, while this characteristic was not as important to adults or parents, and elderly patients may well wish for a larger device that is easier to see and hold. Clearly, different patient populations have different priorities and 'wish lists' for an ideal inhaler. A recent study set out to identify the 'wish list' among 250 patients with COPD (21) . The three most important features of an ideal inhaler were being quick to use when needed, overall ease of use and having a counter to show how many doses remained in the device. The study found that the Diskus TM was rated significantly higher than the Handihaler TM for each of these features.
Interchangeability of DPI devices
The findings of some studies have suggested that clinical equivalence can be achieved when generic inhalers are substituted for other DPIs (84) . However, such studies do not accurately reflect real-life situations and the effectiveness of inhaled medication to achieve disease control is the result of a combination of device design, pharmaceutical performance and patient behaviour. The findings of this review have shown that there are wide differences between currently available DPIs in terms of pharmaceutical performance, ease of use and patient preference. It is clear that 'one inhaler does not fit all' and several factors should be taken into consideration when prescribing a dry powder inhaler device. However, two recent reviews have compared the clinical effectiveness of pMDIs with DPIs in the delivery of bronchodilators and corticosteroids in asthma (13, 14) . The conclusion of each review was that 'no evidence was found that alternative inhaler devices (DPIs, breath-actuated pMDI) are more effective than the pMDI for the delivery of b 2 -agonist or corticosteroids in asthma. pMDI remain the most cost-effective delivery devices'. In some ways, the findings of these reviews are not surprising. This is because both reviews concentrated on the results of clinical studies in which patients were selected whose asthma symptoms were stable, and who demonstrated a good inhaler technique and were compliant with the dosing regimen of the study. Furthermore, the treatment periods in many of the studies cited were of short duration and because many of the studies were designed to show equivalence, doses were selected that were at the top of the dose-response curve. Consequently, many of the studies cited in these reviews demonstrated clinical equivalence between a standard pMDI and the alternative inhaler device. The proportion of a dose of medication from a DPI that deposits in the lung during inhalation varies as a result of the device used, the drug delivered and the patient characteristics (85) . A study was conducted in healthy volunteers that compared the lung deposition of 99 This therefore indicates that changing a delivery device can have adverse effects on both the safety and efficacy of an inhaled drug and that DPIs should not be regarded as interchangeable (15) . It is recognised that patient factors such as ease of use and patient preference directly affect treatment compliance. Therefore, if patients are switched from devices that they find simple to operate and like to use, then compliance with therapy may well deteriorate. This, in turn, will result in a loss of symptom control and consequent increases in morbidity and also healthcare costs. Furthermore, substitution of a familiar inhaler with a generic inhaler could confuse the patient causing them to make additional appointments to see their doctor or nurse thereby negating any possible cost savings.
The availability of a DPI that can be used to deliver a range of drugs is important as patients become used to using a particular device effectively. The Diskus TM is available with salmeterol, fluticasone propionate and also the combination of both drugs at three different strengths. Analysis of prescribing habits, by managed care organisations in the USA, has shown that refill rates are higher when patients are prescribed combination inhalers compared with two separate inhalers each containing a single agent (90) . Improving compliance with therapy regimens results in less reliever use, lower exacerbation rates and reduces the overall healthcare costs of respiratory disease (91) .
Conclusions
National and international guidelines state that the aim of asthma management is to achieve optimal disease control (92) (93) (94) . Poorly controlled asthma results in increased exacerbations of symptoms and resultant healthcare costs (95) and also negatively impacts quality of life (96) . Poorly controlled COPD also results in an increased rate of disease progression, exacerbations requiring hospitalisation and ultimately mortality. Fundamental to achieving optimal disease control in both asthma and COPD is the provision of effective and reliable treatment. DPIs have become popular for the delivery of inhaled medications for both asthma and COPD. Improvements in technology and pharmaceutical science have facilitated the development of DPIs that are simple to use, provide consistent dosing of drug and are liked by patients. However, there are still wide variations in these properties among the different makes of DPI available. The prescriber must therefore ensure that the selection of a delivery device is appropriate for the individual patient needs. While it has been suggested that it is acceptable to swap a patient to the cheapest device available without compromising disease control, this is not supported by the clinical evidence that clearly demonstrates that there are wide differences between the quality of treatment delivered by different DPIs. The 'ideal' dry powder inhaler is the one that delivers consistent and reliable doses and is the one that the patient trusts, finds easy to use and prefers over others. While there is no single 'ideal' DPI that fulfils all those criteria for the entire spectrum of patients who use inhaled medications, the evidence suggests that multi-unit dose DPIs such as Diskus TM offer the most reliable and consistent pharmaceutical performance, and are preferred by patients who rate them as the easiest to use.
